

**Anti-IL-12 (IL-12a & IL-12b) Reference Antibody (briakinumab)  
Recombinant Antibody  
Catalog # APR10466****Specification**

---

**Anti-IL-12 (IL-12a & IL-12b) Reference Antibody (briakinumab) - Product Information**

Application	FC, E, FTA
Primary Accession	<a href="#">P29459</a>
Reactivity	Cynomolgus, Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	143.86 KDa

**Anti-IL-12 (IL-12a & IL-12b) Reference Antibody (briakinumab) - Additional Information****Target/Specificity**

IL-12

**Endotoxin**

&lt; 0.001EU/ µg, determined by LAL method.

**Conjugation**

Unconjugated

**Expression system**

CHO Cell

**Format**

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

**Anti-IL-12 (IL-12a & IL-12b) Reference Antibody (briakinumab) - Protein Information****Name** IL12A**Synonyms** NKSF1**Function**

Heterodimerizes with IL12B to form the IL-12 cytokine or with EBI3/IL27B to form the IL-35 cytokine (PubMed: [8605935](http://www.uniprot.org/citations/8605935), PubMed: [8943050](http://www.uniprot.org/citations/8943050)). IL-12 is primarily produced by professional antigen-presenting cells (APCs) such as B-cells and dendritic cells (DCs) as well as macrophages and granulocytes and regulates T-cell and natural killer-cell responses, induces the production of interferon-gamma (IFN-gamma), favors the differentiation of T-helper 1 (Th1) cells and is an important link between innate resistance and adaptive immunity (PubMed: [1673147](http://www.uniprot.org/citations/1673147), PubMed: [1674604](http://www.uniprot.org/citations/1674604), PubMed: [1674604](http://www.uniprot.org/citations/1674604), PubMed: [1674604](http://www.uniprot.org/citations/1674604)).

<http://www.uniprot.org/citations/8605935> target="\_blank">8605935</a>). Mechanistically, exerts its biological effects through a receptor composed of IL12R1 and IL12R2 subunits (PubMed:<a href="http://www.uniprot.org/citations/8943050" target="\_blank">8943050</a>). Binding to the receptor results in the rapid tyrosine phosphorylation of a number of cellular substrates including the JAK family kinases TYK2 and JAK2 (PubMed:<a href="http://www.uniprot.org/citations/7528775" target="\_blank">7528775</a>). In turn, recruited STAT4 gets phosphorylated and translocates to the nucleus where it regulates cytokine/growth factor responsive genes (PubMed:<a href="http://www.uniprot.org/citations/7638186" target="\_blank">7638186</a>). As part of IL-35, plays essential roles in maintaining the immune homeostasis of the liver microenvironment and functions also as an immune-suppressive cytokine (By similarity). Mediates biological events through unconventional receptors composed of IL12RB2 and gp130/IL6ST heterodimers or homodimers (PubMed:<a href="http://www.uniprot.org/citations/22306691" target="\_blank">22306691</a>). Signaling requires the transcription factors STAT1 and STAT4, which form a unique heterodimer that binds to distinct DNA sites (PubMed:<a href="http://www.uniprot.org/citations/22306691" target="\_blank">22306691</a>).

### Cellular Location


Secreted

### Anti-IL-12 (IL-12a & IL-12b) Reference Antibody (briakinumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### Anti-IL-12 (IL-12a & IL-12b) Reference Antibody (briakinumab) - Images



Anti-IL-12 (IL-12a & IL-12b) Reference Antibody (briakinumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%



The purity of Anti-IL-12 (IL-12a & IL-12b) Reference Antibody (briakinumab) is more than 95% ,determined by SEC-HPLC.